In patients with RAS/RAF wild-type left-sided colon tumors, anti-EGFR plus doublet therapy was associated with numerically superior PFS and OS compared to anti-VEGF plus doublet therapy, though this difference did not reach statistical significance. Here, EGFR is linked to colonic neoplasm.